drugset / Trial / NCT04260932
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients
Phase 1
Completed
12 enrolled
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell lymphoma.
Timeline
- Start
- 2020-03-01
- Primary completion
- 2021-05-10
- Completion
- 2021-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 Dual-CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD19/CD20 Dual-CAR-T cells | Cell therapy | 6e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |